Thrombocytopenia as an initial sign of cirrhosis secondary to hepatic steatosis: a case report

Elvin Omar Videa-Irias1*, Juan Jose Flores Perez2, Daniells Erazo3, David Alejandro Rodas Fino1, Scarlet Betzabel Rodas Gallardo3 and Michelle Elieth Trejo Cruz4

1Internal Medicine Department, School University Hospital, Tegucigalpa M.D.C., Honduras
2Internal Medicine Department, Hospital San Felipe, Tegucigalpa M.D.C., Honduras
3Faculty of Medical Sciences, National Autonomous University of Honduras, Honduras
4Student Faculty of Medical Sciences, National Autonomous University of Honduras, Honduras

Abstract
Cirrhosis is defined as the final stage of a chronic injury that modifies the normal hepatic architecture. Thrombocytopenia is a common complication in patients with chronic liver disease. We report the case of a 66 year-old female who presented to the emergency department with a cramp-type abdominal pain located in the right hypochondrium. Blood tests revealed a hemoglobin level of 11.7 g/dL, leukocyte count of 4,130 /mm³ with neutrophil predominance, platelet count of 98,000 /mm³ with prolonged coagulation times. An abdominal ultrasound reported the finding of cholelithiasis and liver with cirrhotic changes. We concluded that the thrombocytopenia was an initial sign of cirrhosis secondary to non-alcoholic hepatic steatosis with portal hypertension.

Introduction
Cirrhosis is defined as the final stage of a chronic injury in which structural abnormal regenerative nodules are surrounded by fibrous tissue that modifies the normal hepatic architecture [1-3].

Nonalcoholic Steatohepatitis is defined as the excessive accumulation of lipids in the liver, in absence of secondary etiologies such as general or systemic disease, nutritional causes, genetic or metabolic, and drug induced hepatotoxicity. The nonalcoholic steatohepatitis (NASH) is one of the most aggressive clinical presentations of hepatic steatosis, in which the lipid infiltration is followed by intense necroinflammatory activity that can progress to cirrhosis and eventually liver failure and hepatocarcinoma [4,5].

Thrombocytopenia is one of the most important clinical signs at the moment of diagnosis seen in 7 out of 10 patients who were diagnosed with this disease, which can also present sponomegalay and abnormalities in coagulation tests.

Case report
A 66 year old female patient comes to the emergency department presenting cholic abdominal pain located in right hypocondrium treated with analgesics, past medical history report hypertension for about 26 years, obesity grade I diagnosed by the BMI of 32 for 10 years and hepatic steatosis for 9 years, with no history of hepatitis.

A blood test revealed a hemoglobin level of 11.7 g/dl, leukocytes of 4,130 mm³ with neutrophil predominance, platelets 98,000 mm³. After finding thrombocytopenia and for Honduras being an endemic area for arbovirus a serological profile is requested which reports as negative. Coagulation test revealed altered prothrombin and thromboplastin time; other laboratory findings report normal bilirubin and transaminases.

With the possibility that the cause of thrombocytopenia were due to cirrhosis imaging studies were requested, a total abdominal ultrasound and a portal vein Doppler reported liver size of 13 cm with heterogeneous pattern and irregular edges, the portal vein with a flow of 15 -20 cm per second spleen enlarged with 13 cm length (Figure 1), the gallbladder with a 2.1 × 1.4 cm litho (Figure 2), no free liquid was identified; given these findings suspicion of cirrhosis and calculous chronic cholecystitis is confirmed and patient is prepare for cholecystectomy previous platelet transfusion. Cholecystectomy surgery was perfomed where a nodular pattern liver was visualized (Figure 3); a biopsy that reported hepatic tissue with rounded nodules formation of fibrous connective tissue with acute and chronic inflammatory infiltrate, fatty macrovascular metamorphosis 30%.

Figure 1. Spleen enlarged with 13 cm length.
corresponding to Cirrhosis using the Brunt et al., grading and staging NASH it correspond to stage 3 which then develop to stage 4 (Figure 4).

Patient is discharged after surgery with good clinical evolution and a week later an upper digestive endoscopy is perform which rules out the presence of esophageal varices, to its antihypertensive management was added the therapy of antiportal hypertension which was propranolol of 40 mg per day plus L-ornithine L-Aspartate once a day, the last platelets control show improvement with 135,000 mm$^3$ and patient is regularly attending to follow-up medical evaluations (Table 1).

**Discussion**

Thrombocytopenia is often an incidental finding on routine laboratory testing, but can be indicative of important pathology. There are two main mechanisms for thrombocytopenia: (i) decreased production of platelets within the bone marrow and (ii) increased destruction or consumption of platelets in the periphery. The liver plays a key role in haematopoiesis and synthesis of coagulation proteins, therefore liver disease is associated with a broad spectrum of haematological abnormalities. Thrombocytopenia is a common complication in patients with chronic liver disease and is seen in as many as 76% of cirrhotic patients. Traditionally, it was considered that thrombocytopenia in liver disease was exclusively due to increased pooling of platelets in an enlarged spleen, secondary to portal hypertension and extensive cirrhosis [6].

Liver disease was the most common cause for thrombocytopenia in outpatients, a common phenomenon caused by portal hypertension and congestive splenomegaly. The spleen can sequestrate around 90% of platelets in the bloodstream, even though it isn’t rare to observe platelet serum levels below 50,000 cc, other prevalent causes included immune thrombocytopenic purpura (ITP) and primary bone marrow disorder. In inpatients, the causes of thrombocytopenia were more varied; liver disease accounted alongside sepsis/infection, anemia, folic acid deficiency, direct alcohol toxicity, hypersplenism, and bone marrow suppression [1,6].

| Blood Count | Day 1 | Day 7 | Day 23 | Differential | Day 1 | Day 7 | Day 23 |
|-------------|-------|-------|--------|--------------|-------|-------|--------|
| Leukocytes  | 4.13  | 7.80  | 4.09   | Neutrophils  | 2.07  | 6.16  | 2.03   |
| Erythrocytes| 4.51  | 4.20  | 4.18   | Neutrophils %| 50.20 | 78.90 | 49.70  |
| Hemoglobin  | 12.30 | 11.50 | 11.70  | Lymphocytes  | 1.66  | 1.21  | 1.60   |
| Hematocrit  | 36.70 | 33.90 | 34.80  | Lymphocytes %| 40.2  | 15.50 | 39.1   |
| Mean corpuscular volume | 81.40 | 80.70 | 83.30  | Monocytes    | 0.38  | 0.41  | 0.44   |
| MCH         | 27.3  | 27.40 | 28.00  | Monocytes %  | 9.20  | 5.30  | 10.8   |
| MCHC        | 33.5  | 33.90 | 33.6   | Eosinophil   | 0.01  | 0.00  | 0.01   |
| Platelets   | 98.00 | 108.00| 135.00 | Eosinophil % | 0.20  | 0.00  | 0.20   |
| Mean platelet volume (MPV) | 11.40 | 10.80 | 12.00  | Basophiles   | 0.01  | 0.02  | 0.01   |
| Coagulation |       |       |        | Basophiles % | 0.20  | 0.30  | 0.20   |

**Figure 2. Ultrasound image of the gallbladder With a 2.1 x 1.4 cm Litho.**

**Figure 3. Nodular pattern liver.**

| Laboratory Exams |     |     |     |     |     |     |     |
|------------------|-----|-----|-----|-----|-----|-----|-----|
| Total bilirubin  | 0.40|     |     |     |     |     |     |
| Direct bilirubin | 0.18|     |     |     |     |     |     |
| Glucose          | 99.14|    |     |     |     |     |     |
| Gamma Glutamyl transpeptidase | 105.73| |     |     |     |     |     |
| Aspartate amino transferase | 30.95| |     |     |     |     |     |
| Alanine transaminase | 17.70| |     |     |     |     |     |

**Table 1. Laboratory Exams.**
Fatty liver is the accumulation of triglycerides and other fats in the liver cells. In some patients, fatty liver may be accompanied by hepatic inflammation and liver cell death. Pathophysiologic mechanisms for fatty liver include (i) decreased mitochondrial fatty acid beta-oxidation (ii) increased endogenous fatty acid synthesis or enhanced delivery of fatty acids to the liver (iii) deficient incorporation or export of triglycerides as very low-density lipoprotein (VLDL) [7].

Four types of different histological variants can be observed in nonalcoholic steatohepatitis: type I showed steatosis alone, type II steatosis with lobular inflammation, type III steatosis with ballooning degeneration and type IV was similar to type III but also featured Mallory–Denk bodies and/or fibrosis [8].

About 10% of patients with NAFLD progress to NASH. Some 40 to 60% of patients with NASH-induced cirrhosis may develop a complication of cirrhosis including Hepatocellular Carcinoma (HCC) after a period of 5 to 7 years of follow-up. 4 to 27% of NASH transform to HCC after the development of cirrhosis. In addition, most patients with HCC in the setting of NASH have also underlying diabetes (64%), obesity (58%) or other manifestations of the MS. Each year, hepatocellular carcinoma is diagnosed in more than half a million people worldwide. Liver cancer is the fifth most common cancer in men and the seventh in women. Hepatocellular carcinoma rarely occurs before the age of 40 years and reaches a peak at approximately 70 years of age [9,10].

To date, several pharmaceutical agents have been used for the treatment of NASH; however, initial management must be focused on lifestyle modification and the reversal of conditions associated with NAFLD.

Lifestyle changes should include nutritional counselling with or without exercise. The pathophysiological basis for this approach is that weight reduction results in the loss of white adipose tissue, which decreases insulin resistance. Exercise can also improve muscular insulin sensitivity, which may improve the impact of insulin resistance on NAFLD. Several studies have shown that weight reduction with a calorie-restricted diet, with or without exercise, results in a significant biochemical improvement in overweight and obese adults and children. A few trials have also shown a significant reduction in ALT values in patients with biopsy proven NAFLD when they are put on calorie-restricted diets with or without exercise Weight reduction is adopted, gradual loss not exceeding 1.6 kg/week should be emphasized through the combination of dietary restrictions and regular aerobic exercise regimen including at least 30 min of exercise three to five times per week [11].

Cirrhosis caused by nonalcoholic steatohepatitis presents platelet alterations, most commonly thrombocytopenia caused by splenomegaly secondary to portal hypertension. Hepatologic abnormalities such as the metabolic syndrome and non-alcoholic fatty liver disease: Which clinical arguments? [12,13].

References

1. Montoro M, Garcia Pagan J (2012) Gastroenterología y Hepatología. Comunidades de la Práctica Clínica. 2nd ed. Ebook. Barcelona 867-890.
2. Schuppan D, Afshald N (2008) Liver cirrhosis. The Lancet371: 838-851. [Crossref]
3. Pinzani, M., Rosselli, M. and Zackermann, M. (2011). Liver cirrhosis. Best Practice & Research Clinical Gastroenterology 25: 281-290. [Crossref]
4. CastroLS, Silva GP (2015) HÍGADO GRASO NO ALCOHÓLICO. Revista Médica Clínica Las Condes 26: 602-612.
5. Barraza EW, StalnikowitzKD (2016) ESTEATOSIS Y ESTEATOHEPATITIS NO ALCOHÓLICA. Revista de la Facultad de Medicina de la UNAM:40-50.
6. Hancor S, Smith B (2013) Liver disease as a cause of thrombocytopenia. JAM: 425-431.
7. Dawn, S. (2016). Fatty Liver: Overview, Pathophysiology, Etiology. Emedicine. Medscape.com.
8. Hashimoto E, Tokushige K, Ludwig J (2014) Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res: 20-28. [Crossref]
9. Rosner M (2013) Fibrosis, i.e. liver fibrosis and cirrhosis, metabolic syndrome and non-alcoholic fatty liver disease: Which clinical arguments?. Annalied Endocrinologie, 74: 115-120. [Crossref]
10. El-Serag HB (2011) Hepatocellular Carcinoma. N Engl J Med:1118-1127. [Crossref]
11. Younossi (2016) Review Article: Current Management of NAFLD and NASH. Medscape.
12. Jimenez Cuadra E (2016) Articulo original. Complicaciones cirrosis hepatica - Portalesmedicos.com.
13. Téllez-Ávila FJ, Chávez-Tapia NC, Torre-Delgadillo A (2007) Trastornos de coagulación en el cirrótico. Revista de investigación clínica. 59: 153-160.
14. Tagle MA, PoggilLM, Ferrari NG, SistuIG, Aguinaac M et al. (2008) Hallazgos clínicos, bioquímicos y de histología hepática en adultos peruanos con sobrepeso y obesos: primer estudio prospectivo nacional. Rev. gastroenterol. Perú 28: 323-331.